The Cell factory group is developing an advanced therapy medicinal product (ATMP) based on polyclonal multivirus specific T cells (MVT-cells) for autologous and allogeneic use. T lymphocytes are stimulated simultaneously by EBV, CMV, BK polyoma virus and Adenovirus peptides mix to generate virusspecific T cells to treat virus related complications after transplant.

Team